Veraxa Biotech moved its bispecific antibody-drug conjugate program VXA-222 into the next collaboration phase after achieving a technical milestone with Omniab. The update signals advancement of the engineering and development work underpinning the bsADC architecture and its pathway to clinical readiness. VXA-222 is built within an alliance structure, where milestone achievement typically determines subsequent investment, resourcing, and development-stage transitions. For bsADC makers, these milestones can also reflect progress on critical manufacturing or payload-linker performance characteristics—key constraints for ADC reproducibility. The company framed the step as moving into the next collaboration phase, implying that pre-defined work packages have been completed and that the program is now set for further development activity under the alliance. While the announcement stops short of clinical endpoints, it remains a noteworthy execution marker for a modality where technical and scale-up risks often delay timelines.